香港聯合交易所有限公司及證券及期貨事務監察委員會對本申請版本的內容概不負責，對其準確性或完整性亦 不發表任何聲明，並明確表示概不就因本申請版本全部或任何部分內容而產生或依賴該等內容而引致的任何損 失承擔任何責任。 Knature Biopharmaceutical Co., Ltd. 康 諾 生 物 製 藥 股 份 有 限 公 司 （「本公司」） （於中華人民共和國註冊成立的股份有限公司） 的申請版本 警告 本申請版本乃根據香港聯合交易所有限公司（「聯交所」）及證券及期貨事務監察委員會（「證監會」）的要求而刊 發，僅用作提供資訊予香港公眾人士。 本申請版本為草擬本，其內所載資訊並不完整，亦可能會作出重大變動。 閣下閱覽本文件，即代表 閣下知 悉、接納並向本公司、本公司的獨家保薦人、整體協調人、顧問及包銷團成員表示同意： 於本公司招股章程根據香港法例第32章《公司（清盤及雜項條文）條例》送呈香港公司註冊處處長登記前，不會向 香港公眾人士提出要約或邀請。 倘在適當時候向香港公眾人士提出要約或邀請，有意投資者務請僅依據向香港公司註冊處處長登記的本公司招 股章程作出投資決定。該文件的文本將於發售期內向公眾人士派發。 ...

香港聯合交易所有限公司及證券及期貨事務監察委員會對本申請版本的內容概不負責，對其準確性或完整性亦 不發表任何聲明，並明確表示概不就因本申請版本全部或任何部分內容而產生或依賴該等內容而引致的任何損 失承擔任何責任。 Knature Biopharmaceutical Co., Ltd. 康 諾 生 物 製 藥 股 份 有 限 公 司 （「本公司」） （於中華人民共和國註冊成立的股份有限公司） 的申請版本 警告 本申請版本乃根據香港聯合交易所有限公司（「聯交所」）及證券及期貨事務監察委員會（「證監會」）的要求而刊 發，僅用作提供資訊予香港公眾人士。 本申請版本為草擬本，其內所載資訊並不完整，亦可能會作出重大變動。 閣下閱覽本文件，即代表 閣下知 悉、接納並向本公司、本公司的獨家保薦人、整體協調人、顧問及包銷團成員表示同意： 於本公司招股章程根據香港法例第32章《公司（清盤及雜項條文）條例》送呈香港公司註冊處處長登記前，不會向 香港公眾人士提出要約或邀請。 倘在適當時候向香港公眾人士提出要約或邀請，有意投資者務請僅依據向香港公司註冊處處長登記的本公司招 股章程作出投資決定。該文件的文本將於發售期內向公眾人士派發。 ...

Company Overview - Dize Pharmaceutical Co., Ltd. is a commercial-stage biopharmaceutical company focused on oncology and hematology diseases, with its core product, Shuwozhe®, being the only approved small molecule EGFR tyrosine kinase inhibitor for treating EGFR 20 insertion mutation lung cancer globally [3] - The company was established in 2017, originating from AstraZeneca's global oncology translational science center, and possesses significant competitive advantages, including a strong research heritage and a mature scientific team with experience in drug discovery and development [3] - Dize has a robust product pipeline, including two approved drugs (Shuwozhe® and Gaoruizhe®), one candidate drug in the registration clinical stage, three assets in the concept validation stage, and one asset in the early clinical stage [3] Product Details - Shuwozhe® has been approved in China and the U.S., recognized as the first lung cancer drug developed in China to receive breakthrough therapy designation from both the FDA and the National Medical Products Administration of China [4] - Gaoruizhe® is the first and only approved JAK1 inhibitor for treating relapsed or refractory peripheral T-cell lymphoma, having received fast track and orphan drug designations from the FDA [4] Financial Performance - The company reported revenues of approximately 91.29 million RMB for the fiscal year 2023, projected to increase to 360 million RMB in 2024 and 586 million RMB in 2025 [5][7] - Research and development expenses were approximately 806 million RMB in 2023, decreasing to 724 million RMB in 2024 and 644 million RMB in 2025 [6][7] - The gross profit margin for the company was approximately 96.5% in 2023, 97.4% in 2024, and 95.7% in 2025 [8] Industry Overview - The global oncology drug market is expected to grow from $167 billion in 2020 to $262 billion by 2024, with a compound annual growth rate (CAGR) of 11.9%, and projected to reach $724.9 billion by 2035 [9] - In China, the oncology drug market is anticipated to expand from $25.8 billion in 2020 to $37.2 billion by 2024, with a CAGR of 13.1%, reaching $143.7 billion by 2035 [9] - Non-small cell lung cancer (NSCLC) accounts for approximately 85% of lung cancer cases, with the global incidence expected to rise from about 1.9 million cases in 2020 to 2.9 million by 2035 [12] - The global NSCLC drug market is projected to grow from $22.5 billion in 2020 to $49.2 billion by 2024, with a CAGR of 21.6%, and expected to reach $97.5 billion by 2035 [12]

Company Overview - DIZHE Pharmaceutical is a commercial-stage biopharmaceutical company focused on oncology and hematology diseases, with its core product, Shuwozhe®, being the only approved small molecule EGFR TKI for treating EGFR 20 insertion mutation lung cancer globally [2] - Founded in 2017, DIZHE originated from AstraZeneca's Global Oncology Translational Science Center, possessing significant competitive advantages in drug discovery and development [2] - The company has a robust product pipeline, including two approved drugs (Shuwozhe® and Gaoruizhe®), one candidate in the registration clinical stage, three assets in the concept validation stage, and one in early clinical stage [2] Product Information - Shuwozhe® is the first lung cancer drug developed in China to receive both FDA and NMPA breakthrough therapy designations, and it is the only drug recommended by the NCCN guidelines for treating EGFR 20 insertion mutation NSCLC [3] - Gaoruizhe® is the first and only approved JAK1 inhibitor for treating relapsed or refractory peripheral T-cell lymphoma, having received fast track and orphan drug designations from the FDA [3] Financial Performance - Revenue for the fiscal years 2023, 2024, and the nine months ending September 30, 2025, were approximately RMB 91.29 million, RMB 359.90 million, and RMB 586.30 million respectively [4] - Research and development expenses for the same periods were approximately RMB 806 million, RMB 724 million, and RMB 644 million respectively [5] - Gross profit margins for 2023, 2024, and the nine months ending September 30, 2025, were approximately 96.5%, 97.4%, and 95.7% respectively [8] Industry Overview - The global oncology drug market is projected to grow from USD 167 billion in 2020 to USD 262 billion by 2024, with a CAGR of 11.9%, and is expected to reach USD 724.9 billion by 2035 [9] - In China, the oncology drug market is expected to grow from USD 25.8 billion in 2020 to USD 37.2 billion by 2024, with a CAGR of 13.1%, reaching USD 143.7 billion by 2035 [9] - Non-small cell lung cancer (NSCLC) accounts for approximately 85% of lung cancer cases, with the global incidence expected to rise from about 1.9 million cases in 2020 to 2.9 million by 2035 [11] - The global NSCLC drug market is anticipated to grow from USD 22.5 billion in 2020 to USD 49.2 billion by 2024, with a CAGR of 21.6%, and is projected to reach USD 97.5 billion by 2035 [11] - The market for EGFR 20 insertion mutation NSCLC is expected to grow from USD 700 million in 2020 to USD 1 billion by 2024, with a CAGR of 9.0%, and is projected to reach USD 8 billion by 2035 [13]

Company Overview - Dize Pharmaceutical Co., Ltd. is a commercial-stage biopharmaceutical company focused on oncology and hematological diseases, with its core product, Shuwozhe®, being the only approved small molecule EGFR tyrosine kinase inhibitor for treating EGFR 20 insertion mutation lung cancer globally [3][4] - Founded in 2017, Dize originated from AstraZeneca's global oncology translational science center, possessing significant competitive advantages in drug discovery and development [3] - The company has a robust product pipeline, including two approved drugs (Shuwozhe® and Gaoruozhe®), one candidate in the registration clinical stage, three assets in the concept validation stage, and one in early clinical stage [3] Financial Performance - Revenue for the fiscal years 2023, 2024, and the nine months ending September 30, 2025, were approximately RMB 91.29 million, RMB 360 million, and RMB 586 million respectively [5][7] - Research and development expenses for the same periods were approximately RMB 806 million, RMB 724 million, and RMB 644 million respectively [6][8] - Gross profit margins for 2023, 2024, and the nine months ending September 30, 2025, were approximately 96.5%, 97.4%, and 95.7% respectively [9][10] Industry Overview - The global oncology drug market is projected to grow from USD 167 billion in 2020 to USD 262 billion by 2024, with a compound annual growth rate (CAGR) of 11.9%, and expected to reach USD 724.9 billion by 2035 [11] - In China, the oncology drug market is expected to grow from USD 25.8 billion in 2020 to USD 37.2 billion by 2024, with a CAGR of 13.1%, reaching USD 143.7 billion by 2035 [11] - Non-small cell lung cancer (NSCLC) accounts for approximately 85% of lung cancer cases, with the global incidence expected to rise from about 1.9 million cases in 2020 to 2.9 million by 2035 [14] - The global NSCLC drug market is projected to grow from USD 22.5 billion in 2020 to USD 49.2 billion by 2024, with a CAGR of 21.6%, and expected to reach USD 97.5 billion by 2035 [14]

Group 1 - The core viewpoint of the article is that Dize Pharmaceutical (Jiangsu) Co., Ltd. has submitted its listing application to the Hong Kong Stock Exchange, with Goldman Sachs and Huatai International as joint sponsors [1] - Dize Pharmaceutical is a commercial-stage biopharmaceutical company focusing on the treatment of oncology and hematological diseases [1] - The company's flagship product, Shuwozhe®, is the only approved small molecule epidermal growth factor receptor tyrosine kinase inhibitor globally for treating EGFR exon 20 insertion mutation lung cancer [1]

Group 1 - The core viewpoint of the article is that Dize Pharmaceutical (688192.SH) has submitted its listing application to the Hong Kong Stock Exchange, with Goldman Sachs and Huatai International as joint sponsors [1] - Dize Pharmaceutical is a commercial-stage biopharmaceutical company focusing on the treatment of oncology and hematological diseases [1] - The company's flagship product, Shuwozhe®, is the only approved small molecule epidermal growth factor receptor tyrosine kinase inhibitor globally for treating EGFR exon 20 insertion mutation lung cancer [1]

Group 1 - The core viewpoint of the article is that Dize Pharmaceutical (Jiangsu) Co., Ltd. has submitted its listing application to the Hong Kong Stock Exchange, with Goldman Sachs and Huatai International as joint sponsors [1] - Dize Pharmaceutical is a commercial-stage biopharmaceutical company focusing on the treatment of oncology and hematological diseases [1] - The company's listed product, Shuwozhe, is the only approved small molecule epidermal growth factor receptor tyrosine kinase inhibitor globally for treating EGFR exon 20 insertion mutation lung cancer [1]

Core Viewpoint - Northeast Pharmaceutical (000597) has completed the acquisition of a 70% stake in Beijing Dingcheng Peptide Source Biotechnology Co., Ltd. for approximately 187 million yuan, enhancing its capabilities in TCR-T and CAR-T cell therapy technologies and product transformation systems [1] Group 1: Acquisition Details - The acquisition was finalized on November 2024, with a cash payment of about 187 million yuan [1] - The company has gained access to a technology platform and product transformation system in the TCR-T and CAR-T cell therapy fields [1] Group 2: Product Development - Dingcheng Peptide Source's core product, DCTY1102 injection, has received implied approval for clinical trials from the CDE, positioning it to become the second globally and the first domestically targeted KRAS G12D TCR-T cell drug to enter Phase I clinical trials [1] - Another product, DCTY0801, has successfully obtained orphan drug designation from the FDA in the United States [1]

Core Viewpoint - The recent decision by the Nasdaq Hearing Committee allows Sinovac Biotech Ltd. to maintain its listing status on the Nasdaq Global Market, contingent upon the timely submission of financial reports by May 11, 2026 [5][6]. Group 1: Financial Reporting and Compliance - Sinovac must complete the submission of its annual financial report for the fiscal year ending December 31, 2024, and the interim financial report for the second quarter of 2025 by May 11, 2026 [6][7]. - The company has engaged Zhonghua Certified Public Accountants to conduct independent audits and is working collaboratively to meet the reporting requirements [7][8]. Group 2: Historical Performance and Challenges - Sinovac's revenue peaked in 2021 with a total revenue of 135.49 billion yuan, reflecting a year-on-year increase of 3694.36%, and a net profit of 59.21 billion yuan, up 7571.97% [9]. - However, the demand for COVID-19 vaccines has sharply declined, leading to significant revenue drops of 92.30% in 2022 and 69.97% in 2023, with net profits decreasing by 98.66% and 187.75% respectively [9]. Group 3: Product Pipeline and Market Expansion - Sinovac has a diverse product pipeline beyond COVID-19 vaccines, including vaccines for hepatitis A, influenza, varicella, and inactivated polio vaccines [9]. - Recent approvals for new products, such as the 23-valent pneumococcal polysaccharide vaccine, and successful bids for international orders, indicate a potential for growth in international markets [9]. Group 4: Governance Issues - Sinovac has faced ongoing internal governance challenges, stemming from a power struggle between co-founders, which has led to significant operational disruptions [10][11]. - The company has been under scrutiny for governance failures, resulting in its stock being suspended by Nasdaq in 2019 [12].